Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.38 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509196 | 0.85 | ADORA3 (0.46) | KDM4ENPC1RAB9ACYP1A2GAA | |
| SCHEMBL13844297 | 0.81 | HTT (0.47) | KDM4ENPC1RAB9ACYP1A2CYP2C9 | |
| SCHEMBL16509324 | 0.77 | NPC1 (0.50) | KDM4ENPC1RAB9ACYP1A2GAA | |
| SCHEMBL16509296 | 0.77 | KDM4E (0.50) | KDM4ENPC1RAB9ACYP1A2GAA | |
| SCHEMBL14922007 | 0.77 | KDM4E (0.69) | KDM4ENPC1RAB9ACYP1A2GAA | |
| SCHEMBL16509244 | 0.75 | ADORA3 (0.51) | KDM4ENPC1RAB9ACYP1A2GAA | |
| SCHEMBL16509206 | 0.75 | RAB9A (0.51) | KDM4ENPC1RAB9ACYP1A2GAA | |
| SCHEMBL16509266 | 0.75 | RAB9A (0.48) | KDM4ENPC1RAB9ACYP1A2GAA | |
| SCHEMBL16509173 | 0.75 | RORC (0.67) | GAASMN1; SMN2RORC | |
| SCHEMBL16509299 | 0.74 | KDM4E (0.56) | KDM4ENPC1RAB9ACYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | GRM5 4389/4885KDM4E 360/4885NPC1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.